Organogenesis Completes BLA for Renu Knee Osteoarthritis

Organogenesis completed a rolling Biologics License Application (BLA) submission to the US FDA for Renu (cryopreserved amniotic suspension allograft), seeking approval for the management of symptomatic knee osteoarthritis. The filing, announced on April 28, 2026, marks the first BLA submission for a cryopreserved amniotic suspension allograft in this indication and follows a rolling submission process that began in December 2025 with non-clinical modules.

Organogenesis initiated the rolling submission strategy in December 2025, submitting non-clinical modules first before completing the package with clinical and chemistry, manufacturing, and controls modules in April 2026. The company said the filing seeks approval based on data from three randomized controlled trials enrolling more than 1,300 patients. Renu previously held FDA Regenerative Medicine Advanced Therapy designation for knee OA, granted in 2021, and was commercially available for approximately six years under Section 361 of the Public Health Service Act before the BLA pathway became necessary. The company has not disclosed a PDUFA target action date.

Renu consists of amniotic fluid cells and micronized amniotic membrane, delivering cellular, growth factor, and extracellular matrix components into the joint. The product does not carry a single defined molecular target in the manner of a conventional receptor-directed drug; its mechanism is characterized as broad anti-inflammatory, immunomodulatory, and regenerative activity mediated through the biological constituents of amniotic tissue.

Knee OA affects an estimated 31.1 million Americans, a figure the company projects will reach 34.4 million by 2027. The condition is among the leading causes of chronic pain and functional limitation, and its end-stage management typically involves total knee arthroplasty when other options are exhausted. The current standard of care remains entirely symptomatic: oral and topical NSAIDs, intra-articular corticosteroids, and hyaluronic acid injections address pain without modifying underlying disease. No FDA-approved biologic or regenerative therapy exists specifically for knee OA, and no disease-modifying agent has cleared the regulatory threshold despite decades of development attempts. The Renu BLA submission enters a field where a separate NDA for lorecivivint, a CLK/DYRK kinase inhibitor submitted by Biosplice Therapeutics in January 2026, is also under FDA review, reflecting a broader convergence of late-stage development activity in an indication long characterized by therapeutic stagnation.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article

The AllSci Brief